Vaccines to Breast Cancer Based on p53 Mutants
Abstract
The aim of this proposal is to test vaccines expressing mouse mutant or wild-type p53 for induction of protective immunity against challenge with tumor cell lines expressing either mutant or high levels of wild-type p53. The long term goal is to develop an efficacious vaccine with broad applicability for the treatment of human breast cancer patients. Our studies to date show that vaccinia virus recombinants expressing full-length wild-type p53 provide up to 70% protection to one of the model tumor cell lines under investigation. Vaccine efficacy can be improved by using mouse IL-l2 as an adjuvant.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 1997
- Accession Number
- ADA337557
Entities
People
- Hildegund C. Ertl
Organizations
- Wistar Institute